MedTrace Logo

Development of an Intranasal Proteosome Influenza Vaccine

NCT02522754 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2015-08-13

No results posted yet for this study

Summary

A study to compare multiple dosage regimes of a protesomal intranasal vaccine.

Conditions

Interventions

BIOLOGICAL

Placebo Protesomal Vaccine

Intranasal vaccine Protesomal Vaccine

BIOLOGICAL

Experimental: Protesomal Vaccine 1 x 30 µg

Experimental: Protesomal Vaccine 1 x 30 µg

BIOLOGICAL

Experimental: Protesomal Vaccine 2 x 30 µg

Experimental: Protesomal Vaccine 2 x 30 µg

BIOLOGICAL

Experimental: Protesomal Vaccine 2 x 15 µg

Experimental: Protesomal Vaccine 2 x 15 µg

Sponsors & Collaborators

Principal Investigators

  • Rob Lambkin-Williams, PhD · PI

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2004-01-31
Completion
2004-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02522754 on ClinicalTrials.gov